Clinical trials: Protein-Losing Enteropathies
Dopamine, Protein-Losing Enteropathies
Characterizing the Effect of Dopamine on Markers of Lymph Re-circulation in Fontan-associated Protein-losing Enteropathy
Patients that have undergone a Fontan procedure (surgical correction for single ventricle congenital heart disease) may develop a complication known as protein-losing enteropathy (PLE).
- Conditions
- Dopamine, Protein-Losing Enteropathies, Lymphatic System, Lymph
- Trial name
- NCT03322345
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Michigan
Plastic Bronchitis, Protein-Losing Enteropathies
Inhaled Tissue Plasminogen Activator for Acute Plastic Bronchitis
Plastic bronchitis (PB) is a rare, most often pediatric disease characterized by the formation of obstructive airway casts primarily composed of fibrin.
- Conditions
- Plastic Bronchitis, Protein-Losing Enteropathies, Healthy
- Trial name
- PLATyPuS (NCT02315898)
- Testing
- Treatment-inhaled tPA
- Where
- 6 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Lymphatic Diseases, Lymphatic Abnormalities
A Prospective Natural History Study of Lymphatic Anomalies
Background: The lymphatic system is a network of vessels that carry a clear fluid called lymph through the body. Problems in the lymphatic system can cause pain, fluid buildup, and issues with immunity.
- Trial name
- NCT05731141
- Where
- 2 sites in United States
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Protein Losing Enteropathy
Pilot/Ph I Safety and Efficacy of ODSH in Protein Losing Enteropathy Secondary to Single Ventricle Palliative Surgery
Protein Losing Enteropathy (PLE) is a serious medical condition that may develop in children and adults with congenital heart disease for which a palliative procedure known as the "Fontan procedure" has been performed.
- Trial name
- NCT01161641
- Testing
- ODSH at 0.125 mg/kg/h, ODSH at 0.375 mg/kg/h, ODSH at 0.250 mg/kg/h
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- Jazz Pharmaceuticals
CD55-Deficient Protein-Losing Enteropathy
Compassionate Use of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy
The program is to provide access to an experimental drug called pozelimab and to document the long-term safety of pozelimab in patients with Protein-Losing Enteropathy (PLE).
- Trial name
- CHAPLE Disease (NCT06003881)
- Testing
- Pozelimab
- Sponsor
- Regeneron Pharmaceuticals
CDG Ib
Study of ORL-1M (D-mannose) in Patients With CDG-Ib
Study of ORL-1M in Patients With CDG-Ib
- Trial name
- NCT03404869
- Testing
- ORL-1M - D-mannose
- Where
- Turkey (Türkiye)
- Volunteers
- 5 people
- Sponsor
- Orpha Labs
Lymphatic Disorders, Plastic Bronchitis
European Registry Study on Lymphatic Interventions
This European multicenter observational study aims to evaluate the real-world use, timing, and outcomes of lymphatic interventions in patients with congenital heart disease and/or primary lymphatic disorders.
- Conditions
- Lymphatic Disorders, Plastic Bronchitis, Protein Losing Enteropathy, Chylothorax
- Trial name
- EURO-LYMPH (NCT07131293)
- Testing
- Lymphatic intervention
- Where
- Denmark
- Volunteers
- 500 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Fontan Physiology Patients With PB or PLE, Fontan Physiology Patients Without PB or PLE
Plastic Bronchitis and Protein Losing Enteropathy in Children With Single Ventricle Physiology
The investigators are studying what causes Plastic Bronchitis and Protein Losing Enteropathy. The investigators think that these problems are from too much of two small proteins called Vasoactive Intestinal Peptide (VIP) and…
- Trial name
- NCT01563757
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Medical College of Wisconsin
Fontan Operation, Protein-Losing Enteropathy
Camostat Mesylate for Protein-losing Enteropathy After Fontan Operation
This study is phase 2 open-label, single-arm, multi-center clinical trial to evaluate the efficacy and safety of Camostat mesylate in patients with Protein-losing enteropathy after Fontan operation.
- Conditions
- Fontan Operation, Protein-Losing Enteropathy, Camostat Mesylate
- Trial name
- NCT05474664
- Testing
- Camostat mesylate
- Where
- South Korea
- Volunteers
- 19 people
- Sponsor
- Seoul National University Hospital
SLE
A Study on Protein Losing Enteropathy In Systemic Lupus Erythematosus
The aim of the current study is to investigate if there is GIT involvement in pt's with SLE particularly protein losing enteropathy also its prevalence among the studied cases and it's relation to disease activity .
- Trial name
- NCT04517240
- Testing
- endoscopy
- Volunteers
- 50 people
- Sponsor
- Assiut University
CHAPLE Disease
A Study to Test the Safety of Pozelimab in Pediatric Participants 1 to 5 Years of Age With a Rare Disease Called CHAPLE (Complement Hyperactivation, Angiopathic Thrombosis, Protein-losing Enteropathy) Disease
This study is researching a drug called pozelimab (called "study drug"). The main aim of this study is to monitor the safety and tolerability of the study drug.
- Trial name
- NCT07142343
- Testing
- Pozelimab
- Where
- Turkey (Türkiye)
- Volunteers
- 5 people
- Sponsor
- Regeneron Pharmaceuticals
Lymphatic Abnormality, Plastic Bronchitis
Lymphatic Morphology of Fontan Patients
The Fontan procedure has revolutionized the treatment of patients born with a congenital univentricular heart defect. However, over time, it is associated with severe lymphatic complications such as plastic bronchitis…
- Conditions
- Lymphatic Abnormality, Plastic Bronchitis, Protein-Losing Enteropathies, Univentricular Heart
- Trial name
- NCT04163653
- Testing
- Non-contrast MRI, Cardiopulmonary exercise test
- Where
- Denmark
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
CD55-deficient Protein-losing Enteropathy, CHAPLE
Open-Label Efficacy and Safety Study of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease)
The primary objective of the study is to determine the effect of pozelimab on active CD55-deficient protein-losing enteropathy (PLE; CHAPLE).
- Trial name
- NCT04209634
- Testing
- Pozelimab
- Where
- 3 sites in United States, Thailand and 1 more
- Volunteers
- 10 people
- Sponsor
- Regeneron Pharmaceuticals
CD55-deficient Protein-losing Enteropathy
Compassionate Use of Pozelimab
Provide compassionate use of pozelimab
- Trial name
- NCT05232110
- Testing
- Pozelimab
- Sponsor
- Regeneron Pharmaceuticals
CD55 - Cluster of Differentiation Antigen 55 Deficiency, Primary Intestinal Lymphangiectasis
Transcriptome and Metabolic Analyses of CHAPLE Disease
CHAPLE syndrome (complement hyperactivation, angiopathic thrombosis, protein losing enteropathy) is a newly discovered genetic disorder, which is caused by deleterious mutations in the CD55 gene.
- Conditions
- CD55 - Cluster of Differentiation Antigen 55 Deficiency, Primary Intestinal Lymphangiectasis, Protein-Losing Enteropathies, Complement Regulatory Factor Defect
- Trial name
- CHAPLEOMIC (NCT03950804)
- Testing
- Eculizumab Injection
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Marmara University
Lymphedema
International Lymphatic Disease and Lymphedema Registry
The purpose of the International Lymphatic Disease and Lymphedema Patient Registry and Biorepository is to collect health information in order to study the disease classification, natural history, and impact of Lymphatic Disease…
- Trial name
- NCT01336790
- Where
- United States
- Volunteers
- 5,000 people
- Sponsor
- Stanford University
Cancer
68Ga-HSA PET/CT Imaging for Protein-losing Enteropathy
In this project, based on the DTPA-HAS kit, investigators plan to develop a positron nuclide 68Ga labeled DTPA-HSA molecular probe in order to obtain high sensitivity, signal-to-noise ratio and high-resolution PET/CT imaging…
- Trial name
- PLE-PET (NCT06716788)
- Testing
- 68Ga-HSA
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University Cancer Hospital & Institute